194 related articles for article (PubMed ID: 9414600)
1. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
Watabe T; Okuda H; Ogura K
Yakugaku Zasshi; 1997 Nov; 117(10-11):910-21. PubMed ID: 9414600
[TBL] [Abstract][Full Text] [Related]
2. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
3. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi K; Watabe T; Ogura Y
Drug Metab Dispos; 1997 Feb; 25(2):270-3. PubMed ID: 9029059
[TBL] [Abstract][Full Text] [Related]
4. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Nishiyama T; Ogura K; Nagayama S; Ikeda K; Yamaguchi S; Nakamura Y; Kawaguchi Y; Watabe T
Drug Metab Dispos; 1997 May; 25(5):270-3. PubMed ID: 9152608
[TBL] [Abstract][Full Text] [Related]
5. [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].
Watabe T; Ogura K; Nishiyama T
Yakugaku Zasshi; 2002 Aug; 122(8):527-35. PubMed ID: 12187768
[TBL] [Abstract][Full Text] [Related]
6. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine.
Ogura K; Nishiyama T; Takubo H; Kato A; Okuda H; Arakawa K; Fukushima M; Nagayama S; Kawaguchi Y; Watabe T
Cancer Lett; 1998 Jan; 122(1-2):107-13. PubMed ID: 9464498
[TBL] [Abstract][Full Text] [Related]
7. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster.
Yan J; Tyring SK; McCrary MM; Lee PC; Haworth S; Raymond R; Olsen SJ; Diasio RB
Clin Pharmacol Ther; 1997 May; 61(5):563-73. PubMed ID: 9164418
[TBL] [Abstract][Full Text] [Related]
8. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.
Nakayama H; Kinouchi T; Kataoka K; Akimoto S; Matsuda Y; Ohnishi Y
Pharmacogenetics; 1997 Feb; 7(1):35-43. PubMed ID: 9110360
[TBL] [Abstract][Full Text] [Related]
9. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.
Diasio RB
Br J Clin Pharmacol; 1998 Jul; 46(1):1-4. PubMed ID: 9690942
[TBL] [Abstract][Full Text] [Related]
10. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
Kanamitsu SI; Ito K; Okuda H; Ogura K; Watabe T; Muro K; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):467-74. PubMed ID: 10725316
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH.
Nishiyama T; Ogura K; Okuda H; Suda K; Kato A; Watabe T
Mol Pharmacol; 2000 May; 57(5):899-905. PubMed ID: 10779372
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
Ashida N; Ijichi K; Watanabe Y; Machida H
Biochem Pharmacol; 1993 Dec; 46(12):2201-7. PubMed ID: 8274153
[TBL] [Abstract][Full Text] [Related]
13. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Miyauchi S; Imaoka T; Okada T; Motoyama M; Kawaguchi T; Akiyama H; Odomi M
Jpn J Pharmacol; 1996 Feb; 70(2):139-48. PubMed ID: 8866751
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
[TBL] [Abstract][Full Text] [Related]
15. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
16. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
19. Drug delivery of oral anti-cancer fluoropyrimidine agents.
Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
[TBL] [Abstract][Full Text] [Related]
20. Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics.
Watanabe M; Tateishi T; Takezawa N; Tanaka M; Kumai T; Nakaya S; Kobayashi S
Cancer Chemother Pharmacol; 2001 Mar; 47(3):250-4. PubMed ID: 11320669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
